Ignite Creation Date:
2024-05-06 @ 4:30 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05007769
Status:
WITHDRAWN
Last Update Posted:
2021-11-05
First Post:
2021-08-09
Brief Title:
Ramucirumab Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
A Phase II Single-center Open-label Study of Ramucirumab Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC RAN
Status:
WITHDRAWN
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lost funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RAN
Brief Summary:
The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab and in order to evaluate the exact mechanism of action of the combination the investigators propose a comprehensive analysis of paired peripheral blood samples collected during this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None